Hikma Urges Justices To Eye Ruling On Medical Treatment IP

Hikma Pharmaceuticals USA Inc. told the U.S. Supreme Court on Tuesday that its bid for review of a Federal Circuit ruling that would purportedly make all medical treatment methods patent-eligible is...

Already a subscriber? Click here to view full article